1 March 2023 - The March 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new/revised listings of note in the Community Schedule this month.

• Influenza vaccine (quadrivalent, split virion) (Afluria Quad) - new formulation
• Liraglutide (Victoza) - new medicine
• Meningococcal B multicomponent vaccine (Bexsero) - restriction change
• Human rotavirus vaccine (monovalent) (Rotarix) - new formulation

Read New Zealand Pharmaceutical Schedule update